Carlyle is to acquire a significant minority stake in CureApp, Inc, a Japanese medical technology (medtech) company and prescription digital therapeutics provider, for JPY7 billion as part of CureApp’s Series G funding.
Carlyle’s investment brings the total amount of capital raised by CureApp to approximately JPY13.4 billion. Carlyle will have one board seat as part of the transaction.
Founded in 2014 by two physicians, CureApp is one of Japan’s fastest-growing medtechs specialising in the research and development of prescription and non-prescription digital therapeutics. CureApp’s pipeline is currently focused on the areas of non-alcoholic steatohepatitis, alcohol addiction, oncology, and chronic heart failure.
The strategic growth investment by Carlyle will help support CureApp in the rollout of its hypertension PDT app and enable the company to advance its digital therapeutics development pipeline.
Carlyle has invested more than JYP394.4 billion of equity in deals in Japan to-date; and has well-established experience investing in the healthcare sector in the country, with investments in Sunsho Pharmaceutical Co, Solasto Corporation, Qualicaps Co, and Colin Medical Technology. Globally, Carlyle has invested more than $19.5 billion of equity in over 75 deals in the healthcare sector as of 30 June, 2022.
